Johnson & Johnson (NYSE:JNJ) Shares Purchased by Larson Financial Group LLC

Larson Financial Group LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 30.4% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 24,741 shares of the company's stock after buying an additional 5,769 shares during the quarter. Larson Financial Group LLC's holdings in Johnson & Johnson were worth $4,103,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Violich Capital Management Inc. increased its stake in Johnson & Johnson by 0.5% during the 1st quarter. Violich Capital Management Inc. now owns 100,740 shares of the company's stock valued at $16,707,000 after purchasing an additional 523 shares in the last quarter. Sage Mountain Advisors LLC raised its position in shares of Johnson & Johnson by 12.7% in the first quarter. Sage Mountain Advisors LLC now owns 16,408 shares of the company's stock worth $2,721,000 after acquiring an additional 1,844 shares during the period. Wealthfront Advisers LLC boosted its stake in shares of Johnson & Johnson by 58.6% during the 1st quarter. Wealthfront Advisers LLC now owns 252,068 shares of the company's stock worth $41,803,000 after acquiring an additional 93,127 shares in the last quarter. West Family Investments Inc. grew its position in shares of Johnson & Johnson by 9.3% during the 1st quarter. West Family Investments Inc. now owns 11,803 shares of the company's stock valued at $1,957,000 after acquiring an additional 1,008 shares during the period. Finally, BluePointe Capital Management LLC acquired a new position in Johnson & Johnson in the 1st quarter worth about $431,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.9%

JNJ traded up $1.47 on Friday, hitting $164.45. 3,369,264 shares of the company were exchanged, compared to its average volume of 8,121,715. The firm has a 50-day moving average price of $154.10 and a two-hundred day moving average price of $154.84. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a market cap of $395.69 billion, a price-to-earnings ratio of 17.61, a price-to-earnings-growth ratio of 2.21 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter last year, the company earned $2.82 earnings per share. The firm's revenue was up 5.8% compared to the same quarter last year. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.16%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Analyst Ratings Changes

JNJ has been the subject of a number of research analyst reports. Raymond James Financial reduced their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Bank of America boosted their price target on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday. Finally, Barclays raised their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday. Eleven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $174.11.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.